Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for type 2 diabetes
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Periconception glycaemic control in women with type 1 diabetes and risk of major birth defects: population based cohort study in Sweden. OBJECTIVE: To examine the association between maternal type 1 diabetes and the risk of major birth defects according to levels of glycated haemoglobin (HbA1C) within three months before or after estimated conception. DESIGN: Population based historical cohort study using nationwide health registers. SETTING: Sweden, 2003-15. PARTICIPANTS: 2458 singleton (...) liveborn infants of mothers with type 1 diabetes and a glycated haemoglobin measurement within three months before or after estimated conception and 1 159 865 infants of mothers without diabetes. MAIN OUTCOME MEASURES: Major cardiac and non-cardiac birth defects according to glycated haemoglobin levels. RESULTS: 122 cases of major cardiac defects were observed among 2458 infants of mothers with type 1 diabetes. Compared with 15 cases of major cardiac defects per 1000 infants of mothers without diabetes
Controllability in an islet specific regulatory network identifies the transcriptional factor NFATC4, which regulates Type 2 Diabetesassociated genes 29977601 2018 12 21 2056-7189 4 2018 NPJ systems biology and applications NPJ Syst Biol Appl Controllability in an islet specific regulatory network identifies the transcriptional factor NFATC4, which regulates Type 2 Diabetesassociated genes. 25 10.1038/s41540-018-0057-0 Probing the dynamic control features of biological networks represents (...) a new frontier in capturing the dysregulated pathways in complex diseases. Here, using patient samples obtained from a pancreatic islet transplantation program, we constructed a tissue-specific gene regulatory network and used the control centrality (Cc) concept to identify the high control centrality (HiCc) pathways, which might serve as key pathobiological pathways for Type 2 Diabetes (T2D). We found that HiCc pathway genes were significantly enriched with modest GWAS p -values in the DIAbetes
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study 29937430 2018 06 28 1935-5548 2018 Jun 24 Diabetes care Diabetes Care Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. dc180343 10.2337/dc18-0343 Evaluate the efficacy and safety of the dual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized (...) insulin in type 1 diabetes (T1D). The inTandem1 trial, a double-blind, 52-week phase 3 trial, randomized North American adults with T1D to placebo ( n = 268), sotagliflozin 200 mg ( n = 263), or sotagliflozin 400 mg ( n = 262) after 6 weeks of insulin optimization. The primary end point was HbA 1c change from baseline at 24 weeks. HbA 1c , weight, and safety were also assessed through 52 weeks. From a mean baseline of 7.57%, placebo-adjusted HbA 1c reductions were 0.36% and 0.41% with sotagliflozin
HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study 29937431 2018 06 28 1935-5548 2018 Jun 24 Diabetes care Diabetes Care HbA 1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. dc180342 10.2337/dc18-0342 The objective of this study was to evaluate the efficacy and safety (...) of the dual SGLT1 and SGLT2 inhibitor sotagliflozin compared with placebo when combined with optimized insulin in adults with type 1 diabetes (T1D). In a double-blind, 52-week, international phase 3 trial, adults with T1D were randomized to placebo ( n = 258) or once-daily oral sotagliflozin 200 mg ( n = 261) or 400 mg ( n = 263) after 6 weeks of insulin optimization. The primary outcome was change in HbA 1c from baseline to 24 weeks. The first secondary end point was a composite of the proportion
A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study 29895556 2018 06 13 1935-5548 2018 Jun 12 Diabetes care Diabetes Care A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study. dc180168 10.2337/dc18-0168 SENIOR compared the efficacy and safety (...) of insulin glargine 300 units/mL (Gla-300) with glargine 100 units/mL (Gla-100) in older people (≥65 years old) with type 2 diabetes. SENIOR was an open-label, two-arm, parallel-group, multicenter phase 3b trial designed to enroll ∼20% of participants aged ≥75 years. Participants were randomized 1:1 to Gla-300 or Gla-100, titrated to a fasting self-monitored plasma glucose of 5.0-7.2 mmol/L (90-130 mg/dL). In total, 1,014 participants were randomized (mean age: 71 years). Comparable reductions in HbA 1c
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: a randomized, open-label clinical trial 29761615 2018 06 11 1463-1326 2018 May 14 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial. 10.1111/dom.13363 To compare the efficacy and safety of MK-1293 insulin glargine (Mk (...) -Gla) and Lantus (Sa-Gla) in people with type 2 diabetesmellitus (T2DM). This Phase 3, randomized, active-controlled, open-label, 24-week clinical trial (ClinicalTrials.gov number NCT02059187) enrolled 531 participants with T2DM (HbA1c ≤11.0%) either eligible for or currently taking basal insulin (≥10 U/day). Participants were randomized 1:1 to once-daily Mk-Gla (n = 263) or Sa-Gla (n = 263). Titration of insulin was guided by a fasting plasma glucose (FPG)-based dosing algorithm. The primary
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial 29898902 2018 06 14 1935-5548 2018 Jun 13 Diabetes care Diabetes Care Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. dc171825 10.2337/dc17-1825 This study explored neoplasm risk with liraglutide versus placebo in the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome (...) Results) cohort. LEADER (NCT01179048) was an international, phase 3b, randomized, double-blind, controlled trial. Participants aged ≥50 years with type 2 diabetesand high cardiovascular risk were assigned 1:1 to receive liraglutide (≤1.8 mg daily; n = 4,668) or placebo ( n = 4,672) in addition to standard care and monitored for 3.5-5 years (median follow-up 3.8 years). The occurrence of neoplasms was a prespecified, exploratory secondary end point. Post hoc analyses of the time to the first confirmed
Semaglutide for type 2 diabetesmellitus: a systematic review and meta-analysis 29756388 2018 06 11 1463-1326 2018 May 13 Diabetes, obesity & metabolism Diabetes Obes Metab Semaglutide for type 2 diabetesmellitus: A systematic review and meta-analysis. 10.1111/dom.13361 To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. We searched major electronic databases and grey literature sources for randomized (...) GLP-1 meta-analysis semaglutide systematic review type 2 diabetes2018 03 22 2018 04 30 2018 05 09 2018 5 15 6 0 2018 5 15 6 0 2018 5 15 6 0 aheadofprint 29756388 10.1111/dom.13361
Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetesin a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial 29708650 2018 06 06 1463-1326 2018 Apr 30 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetesin a multicentre, double-blind, randomized, parallel-arm, active comparator (...) , phase III trial. 10.1111/dom.13340 To compare the efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide 1.5 and 0.75 mg with glimepiride in East-Asian patients with type 2 diabetes (T2D). In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d). The primary endpoint was assessment
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial 29766635 2018 06 06 1463-1326 2018 May 15 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial. 10.1111/dom.13354 To compare the efficacy and safety of MK-1293 insulin glargine (Mk (...) -Gla; 100 U/mL) with originator insulin glargine, Lantus (Sa-Gla), in people with type 1 diabetes mellitus (T1DM). This phase 3, randomized, active-controlled, open-label, 52-week study (ClinicalTrials.gov NCT02059161) enrolled 508 people with T1DM (HbA1c ≤11.0%; 97 mmol/mol) taking basal and prandial insulin. Participants were randomized 1:1 to once-daily Mk-Gla (n = 245) or Sa-Gla (n = 263). Dose titration of basal insulin was by a pre-breakfast plasma glucose dosing algorithm. The primary
A peer-support lifestyle intervention for preventing type 2 diabetesin India: A cluster-randomized controlled trial of the Kerala Diabetes Prevention Program 29874236 2018 06 10 1549-1676 15 6 2018 Jun PLoS medicine PLoS Med. A peer-support lifestyle intervention for preventing type 2 diabetesin India: A cluster-randomized controlled trial of the Kerala Diabetes Prevention Program. e1002575 10.1371/journal.pmed.1002575 The major efficacy trials on diabetes prevention have used resource (...) -intensive approaches to identify high-risk individuals and deliver lifestyle interventions. Such strategies are not feasible for wider implementation in low- and middle-income countries (LMICs). We aimed to evaluate the effectiveness of a peer-support lifestyle intervention in preventing type 2 diabetesamong high-risk individuals identified on the basis of a simple diabetes risk score. The Kerala Diabetes Prevention Program was a cluster-randomized controlled trial conducted in 60 polling areas
Analysis of Fractures in Patients With Type 2 DiabetesTreated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride 29907581 2018 06 16 1935-5548 2018 Jun 15 Diabetes care Diabetes Care Analysis of Fractures in Patients With Type 2 DiabetesTreated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride. dc171525 10.2337/dc17-1525 To assess the effect of empagliflozin on bone fractures (...) and bone mineral density in patients with type 2 diabetesin pooled placebo-controlled trial data and a head-to-head study versus glimepiride. Pooled data were analyzed from patients who were randomized 1:1:1 to empagliflozin 10 mg, empagliflozin 25 mg, or placebo in phase I-III clinical trials. Data were also analyzed from the EMPA-REG H2H-SU trial in which patients received empagliflozin 25 mg or glimepiride as an add-on to metformin for 104 weeks with a 104-week extension. Bone fracture adverse events (AEs) were
Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes. Importance: In clinical trials of patients with type 2 diabetes, long-acting insulin analogs modestly reduced the risk of nocturnal hypoglycemia compared with human neutral protamine Hagedorn (NPH) insulin, but cost 2 to 10 times more. Outcomes in clinical practice may (...) differ from trial results. Objective: To compare the rates of hypoglycemia-related emergency department (ED) visits or hospital admissions associated with initiation of long-acting insulin analogs vs human NPH insulin in patients with type 2 diabetes. Design, Setting, and Participants: A retrospective observational study using data from Kaiser Permanente of Northern California from January 1, 2006, through September 30, 2015. Patients with type 2 diabeteswho initiated a long-acting insulin analog
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. BACKGROUND: Weight loss is often key in the management of obese or overweight patients with type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight loss. We aimed to assess the efficacy, tolerability, and safety of treatment with MEDI0382, a balanced glucagon-like peptide-1 (...) and glucagon receptor dual agonist developed to provide glycaemic control and weight loss, in patients with type 2 diabetes. METHODS: This randomised, placebo-controlled, double-blind, combined multiple-ascending dose (MAD) and phase 2a study was done at 11 study sites (hospitals and contract research organisations) in Germany. We enrolled patients aged 18-65 years with controlled type 2 diabetes (glycated haemoglobin A 1c [HbA 1c ] levels of 6·5-8·5% at screening) and a body-mass index between 27 kg/m 2
Type 1 diabetes. Type 1 diabetes is a chronic autoimmune disease characterised by insulin deficiency and resultant hyperglycaemia. Knowledge of type 1 diabetes has rapidly increased over the past 25 years, resulting in a broad understanding about many aspects of the disease, including its genetics, epidemiology, immune and β-cell phenotypes, and disease burden. Interventions to preserve β cells have been tested, and several methods to improve clinical disease management have been assessed (...) . However, wide gaps still exist in our understanding of type 1 diabetes and our ability to standardise clinical care and decrease disease-associated complications and burden. This Seminar gives an overview of the current understanding of the disease and potential future directions for research and care.
Genomic insights into the causes of type 2 diabetes. Genome-wide association studies have implicated around 250 genomic regions in predisposition to type 2 diabetes, with evidence for causal variants and genes emerging for several of these regions. Understanding of the underlying mechanisms, including the interplay between β-cell failure, insulin sensitivity, appetite regulation, and adipose storage has been facilitated by the integration of multidimensional data for diabetes-related (...) intermediate phenotypes, detailed genomic annotations, functional experiments, and now multiomic molecular features. Studies in diverse ethnic groups and examples from population isolates have shown the value and need for a broad genomic approach to this global disease. Transethnic discovery efforts and large-scale biobanks in diverse populations and ancestries could help to address some of the Eurocentric bias. Despite rapid progress in the discovery of the highly polygenic architecture of type 2 diabetes
Increase in Adiponectin Level Prevents the Development of Type 2 Diabetesin Japanese Men With Low Adiponectin Levels 29978152 2018 11 14 2472-1972 2 7 2018 Jul 01 Journal of the Endocrine Society J Endocr Soc Increase in Adiponectin Level Prevents the Development of Type 2 Diabetesin Japanese Men With Low Adiponectin Levels. 753-764 10.1210/js.2018-00033 Low serum adiponectin (Ad) level is an important risk factor for the development of type 2 diabetesmellitus (T2DM). To determine whether (...) and Metabolism, Sumitomo Hospital, Osaka, Japan. eng Journal Article 2018 06 14 United States J Endocr Soc 101697997 2472-1972 adiponectin type 2 diabetesmellitus 2018 01 29 2018 06 11 2018 7 7 6 0 2018 7 7 6 0 2018 7 7 6 1 epublish 29978152 10.1210/js.2018-00033 js_201800033 PMC6030829 Nat Med. 2002 Nov;8(11):1288-95 12368907 Ann Rheum Dis. 2017 Nov;76(11):1870-1882 28866649 Lancet. 2003 Jan 18;361(9353):226-8 12547549 Atheroscler Suppl. 2005 May;6(2):7-14 15823491 Int J Obes (Lond). 2008 Dec;32 Suppl 7
Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II DiabetesMellitus and Colorectal Cancer 30084749 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Validation of the Survival Benefits of Metformin in Middle Eastern Patients With Type II DiabetesMellitus and Colorectal Cancer. 1-10 10.1200/JGO.18.00018 Purpose Epidemiologic data from several populations suggest that metformin may decrease cancer risk and mortality in patients (...) with colorectal cancer (CRC) and type II diabetesmellitus (DM). Although type II DM and CRC are major health problems in the Middle East, no investigations have been performed to test the effect metformin has on the outcome of patients with type II DM and CRC who are also treated with metformin. Materials and Methods We retrospectively reviewed the medical records of 1,902 patients diagnosed with CRC at King Hussein Cancer Center between January 2004 and December 2012, and identified 349 patients (18
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes30027137 2018 11 14 2471-254X 2 7 2018 Jul Hepatology communications Hepatol Commun Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes. 778-785 10.1002/hep4.1195 Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of insulin resistance, which is the hallmark of type 2 diabetes (T2D). NAFLD is a known risk factor for developing T2D and has a very (...) of this review is to use the founding principles of the comprehensive type 2 diabetesmanagement algorithm to optimize the management of NAFLD. ( Hepatology Communications 2018;2:778-785). Alkhouri Naim N Texas Liver Institute University of Texas Health San Antonio San Antonio TX. Poordad Fred F Texas Liver Institute University of Texas Health San Antonio San Antonio TX. Lawitz Eric E Texas Liver Institute University of Texas Health San Antonio San Antonio TX. eng Journal Article Review 2018 06 07 United